Organoleptic assessment of halitosis (mean change from baseline) · Adults over 18 years with a clinical or self-assessed diagnosis of halitosis, without significant comorbidity (e.g. diabetes) or…
1 finding from 1 review
Winkel 2003 (2-week trial): mean change (SD) in organoleptic score (scale 0 to 5). 0.05% chlorhexidine + 0.05% cetylpyridinium chloride + 0.14% zinc lactate: -1.13 (1.1), baseline 2.8 (0.5) to 1.5 (1.0) at day 14, P <…
1 study · 40 participants
GRADE not reported
Volatile sulphur compounds (VSC), gas chromatography · Adults over 18 years with a clinical or self-assessed diagnosis of halitosis, without significant comorbidity (e.g. diabetes) or…
1 finding from 1 review
Winkel 2003: mean change (SD) in peak VSC (ppb). Mouthrinse: -120 (92), baseline 292 (141) to 172 (104) at day 14, P < 0.005; Placebo: 8 (145), baseline 352 (161) to 360 (254). The mouthrinse caused a significantly…
1 study · 40 participants
GRADE not reported
Organoleptic assessment of halitosis (mean change from baseline) · Adults over 18 years with a clinical or self-assessed diagnosis of halitosis, without significant comorbidity (e.g. diabetes) or…
1 finding from 1 review
Borden 2002: mean change in organoleptic score (scale 0 to 5). Breath Rx (cetylpyridinium chloride + essential oils + chlorine dioxide + zinc): -0.52 at 2 weeks, -0.41 at 4 weeks; Placebo: 0.23 at 2 weeks, 0.16 at 4…
1 study
GRADE not reported
Organoleptic assessment of halitosis (mean change from baseline) · Adults over 18 years with a clinical or self-assessed diagnosis of halitosis, without significant comorbidity (e.g. diabetes) or…
1 finding from 1 review
Borden 2002: mean change in organoleptic score (scale 0 to 5). Oxygene (chlorine dioxide + zinc): 0 at 2 weeks, 0.06 at 4 weeks; Placebo: 0.23 at 2 weeks, 0.16 at 4 weeks. Oxygene did not appear to reduce organoleptic…
1 study
GRADE not reported
Number of individuals with eating difficulties (8 days after administration); duration of eating difficulties · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
Systemic oral acyclovir led to lower number of individuals with eating difficulties (8 days after… compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Adverse events (tongue and tooth staining) · Adults over 18 years with a clinical or self-assessed diagnosis of halitosis, without significant comorbidity (e.g. diabetes) or…
1 finding from 1 review
Winkel 2003: significantly more tongue staining (P < 0.001) and tooth staining (P < 0.002) were noted with the chlorhexidine + cetylpyridinium chloride + zinc lactate mouthrinse than with placebo.
1 study · 40 participants
GRADE not reported
Organoleptic assessment of halitosis (mean change from baseline) · Adults over 18 years with a clinical or self-assessed diagnosis of halitosis, without significant comorbidity (e.g. diabetes) or…
1 finding from 1 review
Borden 2002: mean change in organoleptic score (scale 0 to 5). Essential oils (Listerine): 0.02 at 2 weeks, 0 at 4 weeks; Placebo: 0.23 at 2 weeks, 0.16 at 4 weeks. Listerine did not reduce organoleptic scores. No…
1 study
GRADE not reported
Difficulty in drinking (number with drinking difficulties) · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
Systemic oral acyclovir led to lower number of individuals with drinking difficulties (8 days after… compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Number of individuals admitted to hospital after administration · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
Systemic oral acyclovir showed no clear difference in number of individuals admitted to hospital after administration compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Volatile sulphur compounds (VSC), halimeter · Adults over 18 years with a clinical or self-assessed diagnosis of halitosis, without significant comorbidity (e.g. diabetes) or…
1 finding from 1 review
Borden 2002: mean change in halimeter-assessed VSC (ppb). Essential oils (Listerine): -43.22 at 2 weeks (48.54% reduction), -68.90 at 4 weeks (77.39% reduction); Placebo: -39.86 at 2 weeks (45.25%), -36.77 at 4 weeks…
1 study
GRADE not reported
Duration of fever · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
1 finding from 1 review
Patient or parental satisfaction (tolerance and acceptability of drug) · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
1 finding from 1 review
Adverse effects · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
1 finding from 1 review
Occlusal intervention as an adjunct to periodontal therapy vs Sham (placebo) occlusal intervention as an adjunct to periodontal therapy
Outcome not reported · Adults (aged 18 years or older) with a clinical diagnosis of (chronic) periodontitis
The review found no eligible studies for this question.
1 finding from 1 review
QoL · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
The review found no eligible studies for this question.
1 finding from 1 review
Mean time to resolution of pain · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
1 finding from 1 review
Amir 1997b: no data available. Ducoulombier 1988: time to resolution of pain, acyclovir (1 day=1, 2 days=1, 3 days=3, 4 days=3, 5 days=1, persistent=0) vs placebo (1 day=0, 2 days=0, 3 days=1, 4 days=2, 5 days=4,…
1 study · 18 participants
GRADE not reported
Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs partially absorbed from GI tract (miconazole,… showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs not absorbed from GI tract showed no clear difference in oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Amphotericin B showed no clear difference in oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review